Literature DB >> 15837370

Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein.

Javier Mota1, Maribel Acosta, Rocio Argotte, Raymunda Figueroa, Armando Méndez, Celso Ramos.   

Abstract

Dengue fever is a growing public health concern around the world and despite vaccine development efforts, there are currently no effective dengue vaccines. In the present study we report the induction of protective antibodies against dengue virus by DNA immunization with domain III (DIII) region of the envelope protein (E) in a mouse model. The DIII region of all four dengue virus serotypes were cloned separately into pcDNA 3 plasmid. Protein expression was tested in COS-7 cells. Each plasmid, or a tetravalent combination, were used to immunize BALB/c mice by intramuscular route. Presence of specific antibodies was evaluated by ELISA, and neutralizing antibodies were tested using a cytopathogenic effect (CPE) inhibition assay in BHK-21 cells, as well as in newborn mice challenged intracranially with dengue 2 virus. Mice immunized with individual DIII constructs or the tetravalent formulation developed antibodies against each corresponding dengue serotype. Antibody titers by ELISA were similar for all serotypes and no significant differences were observed when boosters were administered, although antibody responses were dose-dependent. CPE inhibition assays using Den-2 virus showed neutralization titers of 1:10 in mice immunized with individual DIII plasmid or those immunized with the tetravalent formulations. 43% of newborn mice challenged with Den-2 in combination with sera from mice immunized with Den-2 DIII plasmid were protected, whereas sera from mice immunized with the tetravalent formulation conferred 87% protection. Our results suggest that DIII can be used as a tetravalent DNA formulation to induce neutralizing and protective antibodies against dengue virus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837370     DOI: 10.1016/j.vaccine.2004.12.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection.

Authors:  Hui-Mei Hu; Hsin-Wei Chen; Yu-Ju Hsiao; Szu-Hsien Wu; Han-Hsuan Chung; Chun-Hsiang Hsieh; Pele Chong; Chih-Hsiang Leng; Chien-Hsiung Pan
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

2.  Passive protection assay of monoclonal antibodies against dengue virus in suckling mice.

Authors:  Zongtao Chen; Li-Mei Liu; Na Gao; Xiao-Feng Xu; Jun-Lei Zhang; Jia-Li Wang; Jing An
Journal:  Curr Microbiol       Date:  2009-02-03       Impact factor: 2.188

3.  Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.

Authors:  Matthew D Dunn; Shannan L Rossi; Donald M Carter; Matthew R Vogt; Erin Mehlhop; Michael S Diamond; Ted M Ross
Journal:  Virol J       Date:  2010-05-12       Impact factor: 4.099

4.  Leptospirosis prevalence in patients with initial diagnosis of dengue.

Authors:  A Dircio Montes Sergio; E González Figueroa; Verdalet Guzmán María Saadia; Soler Huerta Elizabeth; Rivas Sánchez Beatriz; M Altuzar Aguilar Víctor; J Navarrete Espinosa
Journal:  J Trop Med       Date:  2012-04-24

5.  A novel single-dose dengue subunit vaccine induces memory immune responses.

Authors:  Chen-Yi Chiang; Shih-Jen Liu; Jy-Ping Tsai; Yi-Shiuan Li; Mei-Yu Chen; Hsueh-Hung Liu; Pele Chong; Chih-Hsiang Leng; Hsin-Wei Chen
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

6.  DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.

Authors:  Adriana S Azevedo; Anna M Y Yamamura; Marcos S Freire; Gisela F Trindade; Myrna Bonaldo; Ricardo Galler; Ada M B Alves
Journal:  PLoS One       Date:  2011-07-11       Impact factor: 3.240

7.  An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes.

Authors:  Saima Khanam; Pilankatta Rajendra; Navin Khanna; Sathyamangalam Swaminathan
Journal:  BMC Biotechnol       Date:  2007-02-15       Impact factor: 2.563

8.  Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus.

Authors:  Samantha Brandler; Marianne Lucas-Hourani; Arnaud Moris; Marie-Pascale Frenkiel; Chantal Combredet; Michèle Février; Hugues Bedouelle; Olivier Schwartz; Philippe Desprès; Frédéric Tangy
Journal:  PLoS Negl Trop Dis       Date:  2007-12-12

9.  Conservation and variability of dengue virus proteins: implications for vaccine design.

Authors:  Asif M Khan; Olivo Miotto; Eduardo J M Nascimento; K N Srinivasan; A T Heiny; Guang Lan Zhang; E T Marques; Tin Wee Tan; Vladimir Brusic; Jerome Salmon; J Thomas August
Journal:  PLoS Negl Trop Dis       Date:  2008-08-13

10.  Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes.

Authors:  Monica Poggianella; José L Slon Campos; Kuan Rong Chan; Hwee Cheng Tan; Marco Bestagno; Eng Eong Ooi; Oscar R Burrone
Journal:  PLoS Negl Trop Dis       Date:  2015-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.